The Israeli company’s COVID-19 drug shows promise in the late stage of coronavirus treatment

FIRST ON FOX: An Israeli public company says it developed the “only late-stage cure for COVID-19” and said the results of its Phase II clinical trial, first published in Fox News, revealed that patients suffering from of severe cases of COVID-19, had a 94% survival rate after being treated with the drug.

The Israeli biotechnology company Bonus BioGroup’s cell therapy MesenCure was administered to 50 hospitalized COVID-19 patients suffering from life-threatening pneumonia and respiratory distress, the company said, noting that 47 of those patients had survived.

“These are the most clinically significant results presented today for the treatment of severe COVID-19 patients,” said Dr. Tomer Bronshtein, Head of Research at Bonus BioGroup Ltd., to Fox News in an exclusive interview.

Bronshtein said the Phase II clinical trial, which was recently completed and took place in several medical centers in Israel, revealed that MesenCure can “rescue three out of four people who are at risk of dying” and “can reduce their hospital stays by half. ” He said it “will speed up their healing in a way that will cause less permanent tissue damage and reduce the risk of ‘long COVID’.”

The Israeli biotechnology company Bonus BioGroup's cell therapy MesenCure

The Israeli biotechnology company Bonus BioGroup’s cell therapy MesenCure
(Bonus BioGroup)

The company noted that for each of the first 30 participants in the clinical trial, two patients who also suffered from severe cases, with similar age and comorbidities, were selected for the “control group” who did not receive MesenCure.

After analyzing the data, the company found that Mesencure reduced approximately 70% of the mortality of severe COVID-19 patients compared to the mortality of the group that did not receive the drug. The company also noted that about half of the patients with severe cases of COVID-19 who were treated with the therapy were discharged from the hospital up to just one day after the end of treatment.

FAUCI: COVID-19 HOSPITALIZATIONS INCREASE AMONG VACCINATED

“MesenCure is a drug made from living cells,” Bronshtein explained, noting that the cells “infuse into the patient” and once the cells “reach their lungs, they fill the inflammation and begin to secrete molecules and compounds that soothe this inflammation.”

The MesenCure study showed that almost all COVID-19 patients taking the drug survived.

The MesenCure study showed that almost all COVID-19 patients taking the drug survived.
(iStock, file)

Bronshtein noted that it also reduces pneumonia and edema, helping patients to “be able to breathe.”

“In parallel, [the cells] also improve what is called the cytokine storm, which is the hyperimmune reaction that worsens in COVID 19, “he added.

Bonus BioGroup argued that it is “necessary to offer a therapeutic option to hospitalized, severe COVID-19 patients” given “vaccines reduce but not completely prevent COVID-19 infection and serious illness, as is the case with drugs, designed for at-home treatment of mild COVID-19 that can reduce but not prevent hospitalization and serious illness. “

PFIZER ASKS US PERMISSIONS TO AUTHORIZE EXPERIMENTAL COVID-19 PILL

“We have a drug that works and we want to use it for good use,” Bronshtein told Fox News, adding that MesenCure is currently only available to COVID-19 patients suffering from severe cases through compassionate use. in Israel.

Bonus BioGroup has applied for emergency use approval for the drug in Israel.

Bonus BioGroup has applied for emergency use approval for the drug in Israel.
(iStock, file)

The Jerusalem Post reported in August that the Ministry of Health had approved the expanded use of MesenCure, which helped 15 out of the 17 patients with severe cases of COVID-19 be released from an Israeli hospital one day after receiving their last dose.

Following the results of the Phase II clinical trial, Bronshtein said that Bonus BioGroup is now seeking emergency use approval starting in Israel. The company also continues to run Phase III investigations.

CLICK HERE TO GET THE FOX NEWS APP

“We hope that once we get the approval in Israel, it will be more easily accepted in the US and in Europe,” Bronshtein told Fox News.

Bonus BioGroup CEO Shai Meretzki told Fox News that he was “very pleased that in less than 18 months we were able to develop a new available treatment for all the serious patients who so far have not had a solution.”

Give a Comment